| Literature DB >> 17154522 |
Aldo Andreani1, Silvia Burnelli, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli, Rita Morigi, Mirella Rambaldi, Lucilla Varoli, Mark W Kunkel.
Abstract
The design and synthesis of anticancer E-3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones is reported. Strong COMPARE correlations among the cell line responses suggest that these compounds may be acting similarly through a combination of different mechanisms of action. The 5-methoxy derivative (2h) was the most active compound with a mean pGI50 of 6.34, and it is now under review by Biological Evaluation Committee of the National Cancer Institute for possible further studies.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17154522 DOI： 10.1021/jm0607808
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446